Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.

Details

Serval ID
serval:BIB_D60E64350838
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Journal
Journal for immunotherapy of cancer
Author(s)
Haanen J., Ernstoff M., Wang Y., Menzies A., Puzanov I., Grivas P., Larkin J., Peters S., Thompson J., Obeid M.
ISSN
2051-1426 (Electronic)
ISSN-L
2051-1426
Publication state
Published
Issued date
06/2020
Peer-reviewed
Oui
Volume
8
Number
1
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams are hesitant to retreat in this scenario, despite the fact that a number of patients may derive clinical benefit from this approach. Balancing such clinical benefit and treatment-related toxicities for each patient is becoming increasingly challenging as more and more patients with cancer are being treated with checkpoint inhibitors. In this manuscript, we provide an extensive overview of the relevant literature on retreatment after toxicity, and suggest prophylactic approaches to minimize the risk of severe irAE following rechallenge with immune checkpoint blockade, since treatment may be lifesaving in a number of occasions.
Keywords
autoimmunity
Pubmed
Open Access
Yes
Create date
25/06/2020 14:58
Last modification date
21/11/2020 6:26
Usage data